A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

December 3, 2025

Study Completion Date

December 3, 2025

Conditions
Obesity
Interventions
DRUG

Survodutide

once weekly subcutaneous injection

DRUG

Placebo matching survodutide

once weekly subcutaneous injection

Trial Locations (28)

453-0812

Hosokawa Surgery Clinic, Aichi, Nagoya

467-8602

Nagoya City University Hospital, Aichi, Nagoya

260-8677

Chiba University Hospital, Chiba, Chiba

501-1194

Gifu University Hospital, Gifu, Gifu

080-0848

Jiyugaoka Yamada Clinic, Hokkaido, Obihiro

660-0861

Yamasaki Family Clinic, Hyogo, Amagasaki

650-0017

Kobe University Hospital, Hyogo, Kobe

231-0023

Motomachi Takatsuka Naika Clinic, Kanagawa, Yokohama

860-0863

Morinagaueno Clinic, Kumamoto, Kumamoto

861-8039

Yoshimura Clinic, Kumamoto, Kumamoto

600-8898

Medical Corporation KEISEIKAI Kajiyama Clinic, Kyoto, Kyoto

601-1495

Ijinkai Takeda General Hospital, Kyoto, Kyoto

545-8586

Osaka Metropolitan University Hospital, Osaka, Osaka

565-0853

OCROM Clinic, Osaka, Suita

359-1141

Saino Clinic, Saitama, Tokorozawa

101-0041

Dojinkinenkai Meiwa Hospital, Tokyo, Chiyoda-ku

101-0065

Suidoubashi Medical Clinic, Tokyo, Chiyoda-ku

103-0027

Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku

103-0028

Tokyo Center Clinic, Tokyo, Chuo-ku

104-0031

Fukuwa Clinic, Tokyo, Chuo-ku

Tokyo Asbo Clinic, Tokyo, Chuo-ku

192-0046

New Medical Research System Clinic, Tokyo, Hachioji

177-0051

Shimamura Kinen Hospital, Tokyo, Nerima-ku

160-0004

Clinical Research Hospital Tokyo, Tokyo, Shinjuku-ku

169-0072

HS Clinic, Tokyo, Shinjuku-ku

160-0008

ToCROM Clinic, Tokyo, Shinjyuku-ku

166-0003

Shinei Medical Healthcare Clinic, Tokyo, Suginami-ku

171-0021

Ikebukuro Metropolitan Clinic, Tokyo, Toshima-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY